rectal cancer
Conditions
Interventions
Experimental group:Intervention: Eligible patients received pelvic radiotherapy with a dose of 46 Gy, tumor boost of 50Gy over a period of 5 weeks. Patients were given choices between capecitabine 150
Sponsors
Enshi Tujia and Miao Autonomous Prefecture Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients with histologically proven adenocarcinoma of the rectum, stages II-III; 2. Eastern Co-operative Oncology Group score is between 0-2; 3. Aged from 18 to 75 years old; 4. ANC>1.5*10^9/L, PLT>100*10^9/L, Hb>9.0g/dl, BIL Colorectal Cancerat normal level or < 1.5*ULN, AST (SGOT), ALT (SGPT) < 2.5*ULN; SCr< 1.5*ULN; 5. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. psychotic patient; 3. Patients with severe,uncontrolled organic lesions or infection, such as decompensated heart, lung, kidney failure can lead to tolerance of chemotherapy; 4. Immune dysfunction , such as HIVaplastic anemialeukemiaetc; 5. using other experimental drugs or paticipate in other clinical trials at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological downstaging rate;Ro resection rate;Sphincter preserving rate;Surgical complication; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-year disease free survival;5-year overall survival; | — |
Countries
China
Contacts
Public ContactChuying Huang
Outcome results
None listed